Results 1 to 10 of about 117 (84)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis

Frontiers in Immunology, 2017
BackgroundDengue hemorrhagic fever is the leading cause of hospitalization and death in children living in Asia and Latin America. There is an urgent need for an effective and safe dengue vaccine to reduce morbidity and mortality in this high-risk ...
Moffat Malisheni, Moffat Malisheni, Moffat Malisheni, Moffat Malisheni, Svetlana F. Khaiboullina, Svetlana F. Khaiboullina, Albert A. Rizvanov, Noah Takah, Noah Takah, Grant Murewanhema, Grant Murewanhema, Matthew Bates, Matthew Bates   +12 more
doaj   +3 more sources

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

Human Vaccines & Immunotherapeutics, 2021
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed ...
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon   +11 more
doaj   +1 more source

Efficacy of Live Attenuated Dengue Vaccines: CYD-TDV, TDV (TAK-003), and TV003/TV005

Folia Medica Indonesiana, 2021
Highlight: • Differences in the efficacy of CYD-TDV versus the other TAK-003 and TV003/TV005 were discussed. • One licensed dengue vaccine is CYD-TDV (Dengvaxia).
Yoseph Jeffry Hertanto, Bernadette Dian Novita   +1 more
doaj   +1 more source

Dengvaxia: the world’s first vaccine for prevention of secondary dengue

Therapeutic Advances in Vaccines and Immunotherapy, 2021
The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV)
Danielle Tully, Carrie L. Griffiths
doaj   +1 more source

Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review

Инфекция и иммунитет, 2021
The use of the vaccine in Asia is still very much limited and remained controversial due to its safety, which has yet been properly assessed and evaluated.
W. R. Wan Ismail, M. Sh. Abdul Majid, H. Y. Li, M. F. Madrim, S.Sh. S. Abdul Rahim, M. S. Jeffree, Z. I. Azhar, H. F. Ghazi, M. R. Hassan   +8 more
doaj   +1 more source

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials. [PDF]

PLoS Neglected Tropical Diseases, 2016
A recombinant live attenuated tetravalent dengue vaccine (CYD-TDV) has been shown to be efficacious in preventing virologically-confirmed dengue disease, severe dengue disease and dengue hospitalization in children aged 2-16 years in Asia and Latin ...
Sophia Gailhardou, Anna Skipetrova, Gustavo H Dayan, John Jezorwski, Melanie Saville, Diane Van der Vliet, T Anh Wartel   +6 more
doaj   +1 more source

Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series

Human Vaccines & Immunotherapeutics, 2020
The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America.
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Jing Jin, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe   +7 more
doaj   +1 more source

Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials. [PDF]

PLoS Neglected Tropical Diseases, 2016
BACKGROUND:Two large-scale efficacy studies with the recombinant yellow fever-17D-dengue virus, live-attenuated, tetravalent dengue vaccine (CYD-TDV) candidate undertaken in Asia (NCT01373281) and Latin America (NCT01374516) demonstrated significant ...
Anke Harenberg, Aymeric de Montfort, Frédérique Jantet-Blaudez, Matthew Bonaparte, Florence Boudet, Melanie Saville, Nicholas Jackson, Bruno Guy   +7 more
doaj   +1 more source

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

BMC Infectious Diseases, 2018
Background The live attenuated tetravalent dengue vaccine (CYD-TDV) is licensed using a 0-, 6- and 12-month schedule in dengue-endemic areas. An effective shorter schedule may provide more rapid, optimal protection of targeted populations during vaccine ...
Judith Kirstein, William Douglas, Manoj Thakur, Mark Boaz, Thomas Papa, Anna Skipetrova, Eric Plennevaux   +6 more
doaj   +1 more source

Hidden heterogeneity and its influence on dengue vaccination impact

Infectious Disease Modelling, 2020
The CYD-TDV vaccine was recently developed to combat dengue, a mosquito-borne viral disease that afflicts millions of people each year throughout the tropical and subtropical world.
Magdalene Walters, T. Alex Perkins
doaj   +1 more source